Researchers at Stockholm University, in collaboration with NBIS bioinformaticians, have revealed the architecture and evolution of a supergene behind efficient cross-pollination, and thus, solved a more than century old mystery.
The study, published in Current Biology, demonstrate the exceptional power of evolution and its ability to find convergent solutions, such as highly efficient cross-pollinating mechanisms.
The infrastructure at SciLifeLab is a prerequisite for Key2Brain’s operations. The start-up company Key2Brain develops small antibody fragments which, when coupled with other proteins or drugs, can cross the blood-brain barrier and reach target molecules inside the brain. The goal is improved treatment for patients suffering from brain diseases. The company currently has projects in preclinical phase.